HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Book section

The Past and the Future of VSTs

Abstract : Viral infections are major complications of Hematopoietic Stem Cell Transplantation (HSCT). As efficacy of anti-viral drugs is limited in absence of immune reconstitution and often associated with severe side effects, infusion of Virus-Specific T cells (VSTs) becomes a promising alternative treatment for viral infections and diseases after HSCT. A lot of improvement in VST generation has been made since 1992, date of first attempts. Regarding stimulation antigen, pools of peptides from viral immunodominant proteins become the best choice compared to whole proteins or other types of antigens. In respect with generation methods, a huge improvement has been done both with cell culture thanks to faster protocols of expansion and with immunomagnetic isolation thanks to fully automated generation of VSTs with a close system. This latest kind of VST generation is fast (within 24 hours), compliant with GMP guidelines and allows a wide distribution among cell therapy laboratories. Furthermore, cell source is no longer limited to the HSCT donor. Third-party donors either related or unrelated are also sought. A promising perspective could be the generation of CART based on VSTs aiming both at targeting the malignant cells and controlling the viral infections simultaneously.
Document type :
Book section
Complete list of metadata

https://hal.univ-lorraine.fr/hal-03628672
Contributor : Céline Huselstein Connect in order to contact the contributor
Submitted on : Saturday, April 2, 2022 - 6:43:00 PM
Last modification on : Tuesday, April 5, 2022 - 5:10:31 PM

Identifiers

Citation

Yingying Wang, Mélanie Gauthier, Caroline Laroye, Véronique Decot, Danièle Bensoussan. The Past and the Future of VSTs. Stem Cells and Regenerative Medicine, 80, IOS Press, pp.194-199, 2021, Biomedical and Health Research, ⟨10.3233/BHR210032⟩. ⟨hal-03628672⟩

Share

Metrics

Record views

10